CytoMed Therapeutics Limited Ordinary Shares (NASDAQ:GDTC) — Market Cap & Net Worth
Market Cap & Net Worth: CytoMed Therapeutics Limited Ordinary Shares (GDTC)
CytoMed Therapeutics Limited Ordinary Shares (NASDAQ:GDTC) has a market capitalization of $11.43 Million ($11.43 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #26533 globally and #5293 in its home market, demonstrating a -3.56% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CytoMed Therapeutics Limited Ordinary Shares's stock price $0.97 by its total outstanding shares 11733712 (11.73 Million). Analyse CytoMed Therapeutics Limited Ordinary Sh (GDTC) cash conversion ratio to see how efficiently the company converts income to cash.
CytoMed Therapeutics Limited Ordinary Shares Market Cap History: 2023 to 2026
CytoMed Therapeutics Limited Ordinary Shares's market capitalization history from 2023 to 2026. Data shows change from $57.50 Million to $11.43 Million (-37.05% CAGR).
Index Memberships
CytoMed Therapeutics Limited Ordinary Shares is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #762 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2508 of 3165 |
Weight: CytoMed Therapeutics Limited Ordinary Shares's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
CytoMed Therapeutics Limited Ordinary Shares Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CytoMed Therapeutics Limited Ordinary Shares's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
767.13x
CytoMed Therapeutics Limited Ordinary Shares's market cap is 767.13 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $57.50 Million | $290.56K | -$3.13 Million | 197.88x | N/A |
| 2024 | $39.89 Million | $52.01K | -$1.88 Million | 767.13x | N/A |
Competitor Companies of GDTC by Market Capitalization
Companies near CytoMed Therapeutics Limited Ordinary Shares in the global market cap rankings as of May 4, 2026.
Key companies related to CytoMed Therapeutics Limited Ordinary Shares by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
CytoMed Therapeutics Limited Ordinary Shares Historical Marketcap From 2023 to 2026
Between 2023 and today, CytoMed Therapeutics Limited Ordinary Shares's market cap moved from $57.50 Million to $ 11.43 Million, with a yearly change of -37.05%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $11.43 Million | -27.04% |
| 2025 | $15.66 Million | -60.74% |
| 2024 | $39.89 Million | -30.61% |
| 2023 | $57.50 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of CytoMed Therapeutics Limited Ordinary Shares was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $11.43 Million USD |
| MoneyControl | $11.43 Million USD |
| MarketWatch | $11.43 Million USD |
| marketcap.company | $11.43 Million USD |
| Reuters | $11.43 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About CytoMed Therapeutics Limited Ordinary Shares
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical tr… Read more